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Plasma B-type natriuretic peptide levels are poorly 
related to the occurrence of ischemia or ventricular 
arrhythmias during symptom-limited exercise  
in low-risk patients
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A b s t r a c t
Introduction: The usefulness of B-type natriuretic peptide (BNP) as a marker 
of ischemia is controversial. BNP levels have predicted arrhythmias in vari-
ous settings, but it is unknown whether they are related to exercise-induced 
ischemic ventricular arrhythmias.
Material and methods: We analyzed in 63 patients (64 ±14 years, 65% male, 
62% with known coronary disease) undergoing exercise stress single-pho-
ton emission computed tomography (SPECT) the association between plas-
ma BNP values (before and 15 min after exercise) and the occurrence of 
ischemia or ventricular arrhythmias during the test.
Results: Exercise test (8.1 ±2.7 min, 7.4 ±8.1 metabolic equivalents, 82 
±12% of maximal predicted heart rate) induced reversible perfusion defects 
in 23 (36%) patients. Eight (13%) patients presented significant arrhythmias 
(≥ 7 ventricular premature complexes/min, couplets, or non-sustained ven-
tricular tachycardia during exercise or in the first minute of recovery). Medi-
an baseline BNP levels were 17.5 (12.4–66.4) pg/ml in patients developing 
scintigraphic ischemia and 45.6 (13.2–107.4) pg/ml in those without isch-
emia (p = 0.137). The BNP levels increased after exercise (34.4 (15.3–65.4)% 
increment over baseline, p < 0.001), but the magnitude of this increase was 
not related to SPECT positivity (35.7 (18.8–65.4)% vs. 27.9 (5.6–64.0)% in 
patients with and without ischemia, respectively, p = 0.304). No significant 
association was found between BNP values (at baseline or their change 
during the test) and ventricular arrhythmias.
Conclusions: Plasma BNP values – at baseline or after exercise – were not 
associated with myocardial ischemia or with ventricular arrhythmia during 
exercise SPECT. These results highlight the limited usefulness of this bio-
marker to assess acute ischemia.
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Introduction 
B-type natriuretic peptide (BNP) is secreted in response to myocardial 
wall stress [1] and has become an established diagnostic and prognos-
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tic marker in patients with heart failure [2, 3]. In 
ischemic heart disease, increased BNP levels have 
been associated with a worse outcome in patients 
with ST-elevation acute myocardial infarction [4, 
5], non-ST elevation acute coronary syndromes 
[6], or stable coronary artery disease [7].
Several studies have analyzed the changes in 
circulating levels of BNP or the amino-terminal por-
tion of the prohormone (NT-proBNP) in response 
to exercise-induced myocardial ischemia. Whereas 
some found a direct association between ischemia 
and the post-ischemic change in BNP levels [8, 9], 
this association was not observed by others [10]. 
This issue is clinically relevant since a potentially 
useful application of BNP could be its measure-
ment as an adjunct to exercise ECG to increase its 
sensitivity or in the emergency room to help guide 
management in patients with chest pain of uncer-
tain coronary origin after standard evaluation.
On the other hand, myocardial stretch is ar-
rhythmogenic [11] and wall stress in the ischemic 
region following coronary occlusion has been 
related to an increased incidence of ventricular 
arrhythmias [12–14]. BNP levels have predicted 
the occurrence of supraventricular or ventricular 
arrhythmias in various clinical settings [15–17], 
but their association with ischemic ventricular ar-
rhythmias remains unexplored.
We assessed whether BNP levels are related to 
the occurrence of ischemia or ventricular arrhyth-
mias during exercise stress test with myocardial 
perfusion imaging.
Material and methods
Patients 
Sixty-three consecutive patients undergoing 
single-photon emission computed tomography 
(SPECT) stress testing for diagnostic (n = 24, 38%) 
or prognostic (n = 39, 62%) purposes were includ-
ed. Our local Ethics Committee approved the study 
and all patients provided informed consent. Data 
were obtained on patients’ age, sex, risk factors 
for coronary artery disease, co-morbidities, previ-
ous cardiac disease and ongoing medications.
Ergometry
Patients underwent standard symptom-limit-
ed treadmill testing with continuous 12-lead ECG 
monitoring. If they failed to attain 80% of max-
imum heart rate in the absence of symptoms or 
ST-segment depression, an intravenous bolus of 
dipyridamole was administered at peak exercise 
[18]. Antianginal medications were not discontin-
ued for prognostic tests. The occurrence of angina 
or ST-segment changes and the occurrence, num-
ber and severity of arrhythmias during exercise 
and during the first minute of recovery were re-
corded. Significant ventricular arrhythmia was de-
fined as the occurrence of ≥ 7 premature ventricu-
lar premature complexes (VPCs)/min either during 
exercise or in the recovery phase or the presence 
of couplets or runs of ventricular tachycardia [19].
Myocardial perfusion imaging
At peak stress, 300 MBq of 99mTc-tetrofosmin 
was administered, and imaging was performed 
immediately afterwards in a dual-head 90º gam-
ma camera (E.CAM, Siemens). Four hours later – 
24 h for patients weighing > 90 kg – a second 800 
MBq injection was administered and imaging was 
repeated. A  17-segment myocardial model was 
used for analysis, with a visual perfusion rating of 
0–4 for each segment by two experienced nuclear 
cardiologists unaware of biomarker data [20]. The 
difference between stress and rest scores was cal-
culated and scintigraphic ischemia was defined as 
a summed difference score ≥ 3. Rest gated SPECT 
was performed and end-systolic and end-diastolic 
indexed volumes were obtained and ejection frac-
tion calculated [20].
Determination of B-type natriuretic peptide 
Venous blood samples were obtained before 
and 15 min after stress testing. Plasma was stored 
at –80ºC and aliquots were thawed for analysis. 
A commercially available immunoassay (98000XR, 
Inverness Medical) was used for measurement of 
serum BNP.
Statistical analysis
Categorical variables are reported as counts and 
percentages. Continuous variables are described 
as mean ± SD or as median (interquartile range) 
if their distribution follows a non-normal pattern. 
Comparison between categorical variables was 
performed by c2 tests, and comparison between 
two continuous variables was performed by Stu-
dent t-tests or by the Mann-Whitney test for 
non-normally distributed variables. Paired com-
parisons involving non-normally distributed vari-
ables were performed by the Wilcoxon rank sum 
test. The Spearman coefficient was used to assess 
the association between two continuous variables. 
P-values < 0.05 were considered significant.
Results
Baseline characteristics
Baseline patients’ characteristics with regard 
to the presence or absence of ischemia are shown 
in Table I. Patients had a significant prevalence of 
coronary risk factors and of documented ischemic 
heart disease. The use of antianginal drugs was 
frequent. Stress-induced myocardial ischemia was 
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more frequent in males, in smokers and in those 
with known coronary artery disease. Echocardi-
ography was available in 29 patients. Three had 
significant non-coronary heart disease (one ob-
structive cardiomyopathy, one moderate aortic re-
gurgitation, and one prior arterial switch surgery 
for transposition of the great arteries) and 9 had 
non-significant valve disease. Systolic pulmonary 
artery pressure was calculated in 12 patients; 
it ranged between 21 mm Hg and 45 mm Hg and 
was > 30 mm Hg in five.
Exercise stress test and nuclear imaging
The results of the exercise stress test are sum-
marized in Table II. Exercise duration averaged 8.1 
±2.7 min, maximum workload 7.4 ±2.8 metabolic 
equivalents, and percentage of maximum predict-
ed heart rate 82 ±12%. Nine (14%) patients had 
angina, which was limiting in 6 (10%). Horizontal 
or downsloping ST-segment depression appeared 
in 13 (21%) patients. Five (8%) patients had 
≥ 0.2 mV of ST depression during exercise. Revers-
ible perfusion defects were observed in 23 (36%) 
patients, and 21 (33%) had fixed defects. Mean 
left ventricular ejection fraction was 57 ±12% and 
was ≤ 50% in 20 (32%) patients. Of these vari-
ables, exercise-induced ischemia was only asso-
ciated with a greater prevalence of fixed defects.
Ventricular arrhythmias
Twenty-three (36%) patients had ventricular 
ectopy during exercise. In these patients, the fre-
quency of VPCs was low (2 [1–21]). Four patients 
(6%) had ≥ 7 VPCs/min during exercise and 4 (6%, 
3 of those and 1 additional patient) had ≥ 7 VPCs 
during the first minute of recovery, 6 (10%) had 
ventricular couplets and 2 had runs of non-sus-
tained ventricular tachycardia (lasting seven and 
18 beats, respectively). Significant arrhythmia, as 
defined above, was present in 8 (13%) patients, 
with similar incidence in those with and without 
ischemia (13% vs. 12%, respectively, p = 1.0).
Plasma B-type natriuretic peptide levels
The BNP values in patients with and without 
ischemia are illustrated in Table III. The median 
value of plasma BNP before exercise was 33.7 
(12.4–83.0) pg/ml, without differences among 
patients presenting or not presenting subsequent 
ischemia. BNP levels increased 15  min after ex-
ercise to 51.7 (14.2–96.5) pg/ml (p < 0.001). This 
Table I. Clinical characteristics
Parameter Overall 
(n = 63)
No ischemia
(n = 40)
Ischemia
(n = 23)
P-value
Age [years] 64 ±14 64 ±14 63 ±14 0.725
Female gender 22 (35%) 19 (48%) 3 (13%) 0.006
Active smoker 24 (40%) 11 (28%) 13 (65%) 0.005
Diabetes mellitus 17 (28%) 12 (30%) 5 (24%) 0.608
Hypertension 43 (70%) 29 (74%) 14 (64%) 0.378
Dyslipidemia 37 (61%) 22 (56%) 15 (68%) 0.366
Peripheral vasculopathy 5 (8%) 2 (5%) 3 (14%) 0.341
Previous stroke 6 (10%) 4 (10%) 2 (9%) 1.0
Renal insufficiency 5 (8%) 3 (8%) 2 (9%) 1.0
Previous heart failure 5 (8%) 4 (10%) 1 (4%) 0.647
Previous myocardial infarction 20 (34%) 9 (24%) 11 (50%) 0.044
Previous coronary revascularization 27 (44%) 13 (34%) 14 (61%) 0.042
Antiplatelet use 44 (72%) 26 (68%) 18 (82%) 0.205
β-blocker use 27 (44%) 15 (38%) 12 (54%) 0.225
Calcium antagonist use 12 (20%) 8 (20%) 4 (18%) 1.0
Nitrate use 20 (32%) 11 (28%) 9 (39%) 0.374
ACEI/ARB use 33 (54%) 24 (62%) 9 (41%) 0.121
Statin use 35 (57%) 24 (62%) 11 (50%) 0.382
ACEI/ARB – angiotensin converting enzyme inhibitor/angiotensin receptor blocker.
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increase was of similar magnitude in patients 
with and without ischemia, whether considered 
as an absolute increment (Figure 1 A) or as a rel-
ative increase over baseline. As compared to the 
remaining patients (n = 56), those with more 
severe ischemia (summed difference score ≥ 6, 
n = 7) also did not have a greater increase in BNP 
levels after exercise, either absolute (7.4 (1.8–9.0) 
vs. 10.7 (1.8–32.0) pg/ml, respectively, p = 0.266) 
or relative (34.4 (25.0–64.3) vs. 35.7 (14.5–66.5) 
pg/ml, respectively, p = 0.630).
Table III also summarizes BNP values in patients 
presenting and not presenting arrhythmias. Both 
groups had similar BNP levels at baseline and after 
exercise and also had similar absolute (Figure 1 B) 
or relative increments in BNP levels after exer-
cise with respect to baseline values. The number 
of VPCs during exercise was not associated with 
BNP levels at baseline (r = 0.147, p = 0.249) or 
15 min after exercise (r = 0.173, p = 0.175) nor 
with the post-exercise absolute (r = 0.057, p = 0.658) 
or relative (r = –0.119, p = 0.354) increase in BNP 
levels with respect to baseline values. The increase 
in BNP after exercise was not significantly differ-
ent in the 2 patients presenting runs of non-sus-
tained ventricular tachycardia during the test and 
in the remaining patients.
As Table IV shows, plasma BNP levels were not 
associated with other results of exercise SPECT, 
except for patients with fixed defects having sig-
nificantly higher baseline BNP levels than those 
without fixed defects, although the increment 
in BNP value after exercise was comparable in 
both groups, and for patients with ≥ 0.2 mV ST 
depression having a  greater relative increase in 
BNP levels. No significant correlation was found 
between plasma BNP value at baseline or its ab-
solute increment after exercise and end-diastolic 
or end-systolic left ventricular volumes or ejec-
tion fraction.
Discussion
In the present study, plasma BNP values – at 
baseline or their increment induced by exercise 
Table II. Exercise stress test characteristics
Parameter Overall 
(n = 63)
No ischemia
(n = 40)
Ischemia
(n = 23)
P-value
Total exercise time [min] 8.1 ±2.7 7.9 ±2.4 8.4 ±3.1 0.469
Maximum workload [METS] 7.4 ±2.8 7.3 ±2.8 7.7 ±2.8 0.560
Percentage of maximum predicted heart rate (%) 82 ±12 83 ±12 80 ±11 0.464
Baseline systolic arterial pressure [mm Hg] 131 ±24 133 ±22 128 ±26 0.445
Peak exercise systolic arterial pressure [mm Hg] 157 ±21 158 ±21 155 ±22 0.555
Peak exercise diastolic arterial pressure [mm Hg] 80 ±9 79 ±9 82 ±8 0.162
Exercise-induced angina 9 (14%) 6 (15%) 3 (13%) 1.0
Exercise-induced ST depression 0.1 mV 13 (21%) 8 (20%) 5 (22%) 1.0
Exercise-induced ST depression 0.2 mV 5 (8%) 3 (8%) 2 (9%) 1.0
Myocardial necrosis 21 (33%) 9 (22%) 12 (52%) 0.016
LV end-diastolic volume [ml/m2] 86 (68–120) 82 (60–102) 94 (76–133) 0.121
LV end-systolic volume [ml/m2] 38 (25–55) 35 (18–53) 44 (27–73) 0.114
LV ejection fraction (%) 57 ±12 59 ±13 54 ±11 0.093
LV – left ventricle, METS – metabolic equivalents.
Table III. Plasma BNP values in relation to exercise-induced ischemia or significant ventricular arrhythmia
Parameter Overall 
(n = 63)
No ischemia
(n = 40)
Ischemia
(n = 23)
P-value No VA  
(n = 55)
VA  
(n = 8)
P-value
Baseline BNP  
[pg/ml]
33.7  
(12.4–83.0)
45.6  
(13.2–107.4)
17.5  
(12.4–66.4)
0. 137 32.1  
(12.2–83.0)
59.4  
(19.1–89.1)
0.403
15-min post-
exercise BNP  
[pg/ml]
51.7  
(14.2–96.5)
60.4  
(17.8–101.4)
28.1  
(14.2–85.6)
0.233 46.8  
(14.2–94.4)
91.4  
(25.8–110.5)
0.269
ΔBNP [pg/ml] 9.3  
(1.8–30.0)
10.0  
(1.9–31.0)
8.5  
(1.8–30.0)
0.937 9.0  
(1.8–28.0)
24.8  
(2.2–38.8)
0.489
Relative increase  
in BNP (%)
34.4  
(15.3–65.4)
27.9  
(5.6–64.0)
35.7  
(18.8–65.4)
0.304 34.0  
(15.3–66.5)
36.3  
(17.3–62.8)
0.901
BNP – type-B natriuretic peptide, VA – ventricular arrhythmia.
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– were not associated with inducible myocardial 
ischemia or with the occurrence of ventricular ar-
rhythmias during exercise stress SPECT.
Plasma B-type natriuretic peptide levels 
and exercise-induced ischemia
In part because of their association with de-
pressed ventricular function and/or heart fail-
ure, increased BNP or NT-proBNP levels predict 
a  worse outcome across the entire spectrum of 
ischemic heart disease [4–7]. NT-proBNP has also 
been shown to contain prognostic information in 
patients with suspected non-ST-segment eleva-
tion acute coronary syndrome [21] and in those 
arriving in the emergency room with a normal or 
nearly normal ECG and no troponin elevation [22, 
23]. However, BNP and NT-proBNP mainly predict 
long-term events [21, 23]; it is unclear that they 
are useful to drive patients’ management [24, 25], 
and their value in the chest pain unit has been 
challenged when high-sensitive assays are used 
for troponin detection [26].
Figure 1. Absolute change in type-B natriuretic peptide levels with regard to the presence or absence of ischemia 
(A) or significant ventricular arrhythmia (B) during exercise test (ranges, medians, and 25th to 75th percentiles)
VA – ventricular arrhythmia.
A B
100
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0
–25
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 No ischemia (n = 40) Ischemia (n = 23)  No significant VA (n = 55) Significant VA (n = 8)
p = 0.937 p = 0.489
Table IV. Plasma BNP values in relation to other results of exercise SPECT
Variable Baseline BNP  
[pg/ml]
15-min post-exer-
cise BNP [pg/ml]
ΔBNP [pg/ml] Relative increase 
in BNP (%)
Angina:
No (n = 54) 34.5 (12.1–81.7) 54.3 (13.6–98.1) 9.2 (1.8–30.5) 35.8 (14.8–65.7)
Yes (n = 9) 24.1 (14.8–116.8) 50.5 (21.4–135.8) 9.4 (2.4–33.0) 24.4 (15.2–48.3)
P-value 0.602 0.716 0.945 0.377
0.1 mV ST depression:
No (n = 50) 32.6 (12.1–83.7) 42.8 (14.0–96.6) 8.4 (1.8–28.0) 27.9 (11.5–61.3)
Yes (n = 13) 50.4 (19.9–90.7) 72.1 (28.7–106.8) 21.4 (3.8–42.7) 56.0 (30.0–76.8)
P-value 0.598 0.292 0.122 0.055
0.2 mV ST depression:
No (n = 58) 33.4 (12.4–83.7) 51.1 (14.2–94.9) 8.8 (1.8–28.0) 30.1 (14.3–61.3)
Yes (n = 5) 50.4 (13.6–105.2) 89.4 (21.4–181.0) 39.0 (7.8–75.8) 70.1 (52.2–76.8)
P-value 0.815 0.392 0.077 0.021
Fixed perfusion defects:
No (n = 42) 26.0 (9.9–70.2) 35.8 (13.0–93.6) 8.4 (1.8–26.4) 34.7 (15.8–58.6)
Yes (n = 21) 66.4 (20.8–99.9) 82.9 (28.2–123.5) 14.4 (2.0–43.4) 28.6 (2.8–69.6)
P-value 0.031 0.052 0.287 0.838
BNP – type-B natriuretic peptide.
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In the present study, BNP levels increased 
shortly after exercise, which concurs with previ-
ous observations in healthy people [8, 27] or in 
patients with suspected or known ischemic heart 
disease [8–10]. Baseline BNP levels were related 
to the existence of fixed defects indicating myo-
cardial necrosis. However, neither baseline BNP 
values nor their increment after exercise were 
associated with myocardial ischemia. Previous 
studies that have analyzed the changes in plasma 
BNP or NT-proBNP in relation to exercise-induced 
ischemia have obtained conflicting results. Foote 
et al. described in 74 patients with coronary artery 
disease referred for exercise SPECT that the incre-
ment in plasma BNP or NT-proBNP 1 min after ex-
ercise was higher in patients with ischemia than 
in those without ischemia, and suggested that 
measuring the change in BNPs might be used to 
increase the sensitivity of exercise ECG for detect-
ing ischemia [8]. Sabatine et al. found in 112 pa- 
tients undergoing exercise SPECT that both base-
line BNP values and their increment after exercise 
were related to the presence and severity of isch-
emia, this association being less pronounced for 
NT-proBNP [9]. In contrast, van der Zee et al. found 
in 101 patients undergoing exercise SPECT that, 
although baseline NT-proBNP values were higher 
in those subsequently developing ischemia, their 
increase after exercise was of similar magnitude 
in patients with and without ischemia [10]. Our re-
sults are at variance with those two former stud-
ies [8, 9] but, overall, concur with van der Zee’s 
results [10].
The reason for the discrepancy among these 
otherwise similar studies is unclear. Although dif-
ferences in populations studied, methodology, re-
sults of exercise SPECT or BNP measurement may 
have played a  role, it is likely that the relatively 
reduced size of the samples and the significant 
variability of BNP determinations [28] have con-
tributed to these conflicting results. Anyway, the 
lack of a consistent increase in BNP values asso-
ciated with acute myocardial ischemia challeng-
es the clinical usefulness of measuring this bio-
marker during exercise ECG test or in chest pain 
units. Increased baseline BNP or NT-proBNP levels 
in patients with inducible myocardial ischemia [9, 
10, 29–31] or admitted to the emergency room 
[32] may just reflect increased wall stress due to 
impaired systolic and/or diastolic function rather 
than myocardial ischemia.
Plasma B-type natriuretic peptide levels 
and ischemic arrhythmias
BNP or NT-proBNP levels have predicted atrial 
arrhythmias after non-cardiac surgery [15] or af-
ter electrical cardioversion [16] and ventricular ar-
rhythmias and sudden death in patients at risk for 
these arrhythmias [17]. Increased wall stress has 
been related to ischemic ventricular arrhythmias 
[12–14], but whether BNP values differ among 
patients with and without exercise-induced, isch-
emic arrhythmias is unknown. In the present 
study, the incidence of ventricular arrhythmias 
during or after the test was low and comparable 
to that reported previously [19, 33, 34]. BNP val-
ues were not significantly related to the presence 
or the frequency of VPCs or more complex arrhyth-
mias during exercise, which is not surprising given 
the rarity of VPCs and arrhythmias and the lack of 
a significant association between BNP values and 
ischemia in our series.
Methodological considerations  
and limitations
The relatively small sample size represents 
a limitation, particularly for the assessment of the 
association between BNP levels and arrhythmias. 
However, the sample size is similar to that of pre-
vious studies showing an association between 
BNP changes and ischemia [8], and the lack of 
a trend in the association between BNP levels and 
the occurrence of ischemia or arrhythmias sug-
gest that the results would not have been differ-
ent with a larger sample size. The limited sample 
size also made it impossible to explore whether 
there were differences in BNP values across sub-
groups of patients with increasing severity of isch-
emia. Although the results of BNP measurements 
in the few patients with more severe scintigraph-
ic ischemia argue against this hypothesis, the 
significantly larger increment in circulating BNP 
levels in patients with greater exercise-induced 
ST-segment depression might suggest that se-
vere ischemia could affect BNP levels. Our results 
cannot be extrapolated to a scenario of prolonged 
ischemia with significant myocardial injury, where 
other pathways play a more prominent role [35, 
36]. Our patients were all-comers undergoing 
a SPECT exercise test for diagnostic or prognostic 
purposes. The results might have been different 
with more stringent inclusion criteria, but then 
the clinical relevance would have been lower. BNP 
values were measured only once after the exer-
cise test, because in previous studies sequential 
determinations had not provided additional infor-
mation [9, 10]. Another limitation is that only BNP 
was analyzed. Combining several biomarkers, par-
ticularly high-sensitive troponin [37], or assessing 
other ECG characteristics exercise [38] might have 
provided more insight in the study of predictors of 
ischemia and arrhythmias.
In conclusion, our findings argue against the 
hypothesis that BNP levels can predict the pres-
ence of ischemia and its extension during exercise 
testing. We also have not found any correlation be-
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tween BNP levels and the incidence of arrhythmia 
during the test. Measuring BNP levels probably has 
little diagnostic utility in patients undergoing ex-
ercise ECG or in those evaluated in the emergency 
room for suspected acute coronary syndrome.
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